MAPKAP1 and Hepatic fibrosis: Although the direct application of CDK1 inhibitors in the treatment of liver fibrosis is still under research, some indirect evidence shows that TCM liver recovery can be significantly inhibited by regulating the CDK1-related signaling pathway (such as MAPKAP-1 signaling pathway), which may be related to the indirect regulation of CDK1 [39].